1160175-86-9Relevant academic research and scientific papers
MUTANT SELECTIVE EGFR INHIBITORS AND METHODS OF USE THEREOF
-
, (2022/04/03)
The disclosure relates to compounds that act as inhibitors of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the compounds; and methods of treating or preventing kinase-mediated disorders, including cancer and other proliferation diseases.
MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS
-
Page/Page column 63; 64, (2021/10/22)
Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein m, n, p, t, A, B, Z, R1, R2 and R3 are as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided. The Mas-Related G-protein (MRGPR) X4 modulators, are in particular isoindolinones and isoquinolinones substituted on the carbocyclic ring. The compounds are useful to treat itch associated conditions, pain associated conditions, or an autoimmune disorder.
Synthesis of dibenzoxepine lactams via a Cu-catalyzed one-pot etherification/aldol condensation cascade reaction: Application toward the total synthesis of aristoyagonine
Lim, Hye Sun,Choi, Young Lok,Heo, Jung-Nyoung
supporting information, p. 4718 - 4721 (2013/10/08)
A general synthesis of dibenzoxepine lactams has been developed using a one-pot Cu-catalyzed etherification/aldol condensation cascade reaction. The reaction of 4-hydroxyisoindolin-1-one with a wide range of 2-bromobenzaldehydes in the presence of a copper catalyst provided various aristoyagonine derivatives in good yields.
